Mead Group: Gene-Environment Initiated Disease Progression in Myeloproliferative Neoplasms — Radcliffe Department of Medicine (ox.ac.uk)

I trained in medicine and haematology at the University of Oxford and UCL and completed my PhD at UCL in 2007. I am currently funded by a CRUK Senior Cancer Research Fellowship.

The overarching focus of my research group is to characterise genetic and cellular heterogeneity in myeloproliferative neoplasms (MPN) and related myeloid neoplasms with the ultimate goal to improve the diagnosis, risk-stratification and treatment of these largely incurable forms of blood cancer. Our work using cutting edge techniques in single cell genomics and in vivo models has revealed hitherto unrecognised heterogeneity of cancer stem cells, including a key role for inflammation in promoting therapy resistance and genetic evolution. Understanding the interplay between genetic, metabolic and inflammatory factors in the clonal evolution of myeloid malignancies is now the key focus of my research group.

My research is closely linked with my clinical practice based at Oxford University Hospitals NHS Trust where I am myeloid clinical lead. I am or have been the principal/chief investigator for over 50 trials. I led the development of JAK2 inhibitor therapies in the UK for patients with MPN as chief investigator, scientific lead or co-investigator on multiple key clinical trials (ROBUST, MAJIC, MITHRIDATE, PERSIST-1 and -2, MPDRC114, PHAZAR, PAC203, FEDORA, PROMise).

ORC-ID

0000-0001-8522-1002